Pharmacokinetics and biodistribution of nanoparticles

被引:1237
作者
Li, Shyh-Dar [1 ]
Huang, Leaf [1 ]
机构
[1] Univ N Carolina, Sch Pharm, Div Mol Pharmaceut, Chapel Hill, NC 27599 USA
关键词
nanoparticles; pharmacokinetics; biodistribution; drug release;
D O I
10.1021/mp800049w
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Nanoparticles show their promise for improving the efficacy of drugs with a narrow therapeutic window or low bioavailability, such as anticancer drugs and nucleic acid-based drugs. The pharmacokinetics (PK) and tissue distribution of the nanoparticles largely define their therapeutic effect and toxicity. Chemical and physical properties of the nanoparticles, including size, surface charge, and surface chemistry, are important factors that determine their PK and biodistribution. The intracellular fate of the nanoparticles after cellular internalization that affects the drug bioavailability is also discussed. Strategies for overcoming barriers for intracellular delivery and drug release are presented. Finally, future directions for improving the PK of nanoparticles and perspectives in the field are discussed.
引用
收藏
页码:496 / 504
页数:9
相关论文
共 71 条
[21]   Cytosolic drug delivery using pH- and light-sensitive liposomes [J].
Gerasimov, OV ;
Boomer, JA ;
Qualls, MM ;
Thompson, DH .
ADVANCED DRUG DELIVERY REVIEWS, 1999, 38 (03) :317-338
[22]   A new approach towards acid sensitive copolymer micelles for drug delivery [J].
Gillies, ER ;
Fréchet, JMJ .
CHEMICAL COMMUNICATIONS, 2003, (14) :1640-1641
[23]  
GORDON KB, 1995, CANCER, V75, P2169, DOI 10.1002/1097-0142(19950415)75:8<2169::AID-CNCR2820750822>3.0.CO
[24]  
2-H
[25]   Immunogenicity and pharmacokinetic attributes of poly(ethylene glycol)-grafted immunoliposomes [J].
Harding, JA ;
Engbers, CM ;
Newman, MS ;
Goldstein, NI ;
Zalipsky, S .
BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES, 1997, 1327 (02) :181-192
[26]   Phase I-II study of pegylated liposomal cisplatin (SPI-077™) in patients with inoperable head and neck cancer [J].
Harrington, KJ ;
Lewanski, CR ;
Northcote, AD ;
Whittaker, J ;
Wellbank, H ;
Vile, RG ;
Peters, AM ;
Stewart, JSW .
ANNALS OF ONCOLOGY, 2001, 12 (04) :493-496
[27]   Phase I trial of doxorubicin-containing low temperature sensitive liposomes in spontaneous canine tumors [J].
Hauck, Marlene L. ;
LaRue, Susan M. ;
Petros, William P. ;
Poulson, Jean M. ;
Yu, Daohai ;
Spasojevic, Ivan ;
Pruitt, Amy F. ;
Klein, Allison ;
Case, Beth ;
Thrall, Donald E. ;
Needha, David ;
Dewhirst, Mark W. .
CLINICAL CANCER RESEARCH, 2006, 12 (13) :4004-4010
[28]   Targeted delivery and triggered release of liposomal doxorubicin enhances cytotoxicity against human B lymphoma cells [J].
Ishida, T ;
Kirchmeier, MJ ;
Moase, EH ;
Zalipsky, S ;
Allen, TM .
BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES, 2001, 1515 (02) :144-158
[29]  
Jensen SS, 2004, MOL CANCER THER, V3, P1451
[30]   A phase II study of STEALTH cisplatin (SPI-77) in patients with advanced non-small cell lung cancer [J].
Kim, ES ;
Lu, C ;
Khuri, FR ;
Tonda, M ;
Glisson, BS ;
Liu, D ;
Jung, M ;
Hong, WK ;
Herbst, RS .
LUNG CANCER, 2001, 34 (03) :427-432